Switch to:
Also traded in: Austria, Brazil, Chile, Germany, Italy, Mexico, Switzerland

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.97
GILD's Cash-to-Debt is ranked lower than
83% of the 1018 Companies
in the Global Biotechnology industry.

( Industry Median: 51.38 vs. GILD: 0.97 )
Ranked among companies with meaningful Cash-to-Debt only.
GILD' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.15  Med: 1.54 Max: 4122.75
Current: 0.97
0.15
4122.75
Equity-to-Asset 0.38
GILD's Equity-to-Asset is ranked lower than
78% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. GILD: 0.38 )
Ranked among companies with meaningful Equity-to-Asset only.
GILD' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.21  Med: 0.62 Max: 0.98
Current: 0.38
0.21
0.98
Debt-to-Equity 1.18
GILD's Debt-to-Equity is ranked lower than
86% of the 487 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. GILD: 1.18 )
Ranked among companies with meaningful Debt-to-Equity only.
GILD' s Debt-to-Equity Range Over the Past 10 Years
Min: 0  Med: 0.35 Max: 2.96
Current: 1.18
0
2.96
Debt-to-EBITDA 1.66
GILD's Debt-to-EBITDA is ranked higher than
57% of the 209 Companies
in the Global Biotechnology industry.

( Industry Median: 1.91 vs. GILD: 1.66 )
Ranked among companies with meaningful Debt-to-EBITDA only.
GILD' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.33  Med: 0.88 Max: 1.94
Current: 1.66
0.33
1.94
Interest Coverage 14.62
GILD's Interest Coverage is ranked lower than
82% of the 496 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. GILD: 14.62 )
Ranked among companies with meaningful Interest Coverage only.
GILD' s Interest Coverage Range Over the Past 10 Years
Min: 11.11  Med: 34.31 Max: 165.23
Current: 14.62
11.11
165.23
Piotroski F-Score: 6
Altman Z-Score: 3.68
Beneish M-Score: -2.84
WACC vs ROIC
6.54%
39.08%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating Margin % 57.78
GILD's Operating Margin % is ranked higher than
98% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -119.18 vs. GILD: 57.78 )
Ranked among companies with meaningful Operating Margin % only.
GILD' s Operating Margin % Range Over the Past 10 Years
Min: 40.39  Med: 50.27 Max: 68
Current: 57.78
40.39
68
Net Margin % 42.22
GILD's Net Margin % is ranked higher than
96% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -105.77 vs. GILD: 42.22 )
Ranked among companies with meaningful Net Margin % only.
GILD' s Net Margin % Range Over the Past 10 Years
Min: 26.72  Med: 37.34 Max: 55.48
Current: 42.22
26.72
55.48
ROE % 55.93
GILD's ROE % is ranked higher than
98% of the 936 Companies
in the Global Biotechnology industry.

( Industry Median: -38.72 vs. GILD: 55.93 )
Ranked among companies with meaningful ROE % only.
GILD' s ROE % Range Over the Past 10 Years
Min: 29.75  Med: 50.37 Max: 106.64
Current: 55.93
29.75
106.64
ROA % 19.58
GILD's ROA % is ranked higher than
97% of the 1025 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. GILD: 19.58 )
Ranked among companies with meaningful ROA % only.
GILD' s ROA % Range Over the Past 10 Years
Min: 13.45  Med: 29.12 Max: 42.28
Current: 19.58
13.45
42.28
ROC (Joel Greenblatt) % 561.45
GILD's ROC (Joel Greenblatt) % is ranked higher than
98% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: -411.81 vs. GILD: 561.45 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
GILD' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 161.64  Med: 183.96 Max: 595.52
Current: 561.45
161.64
595.52
3-Year Revenue Growth Rate 50.20
GILD's 3-Year Revenue Growth Rate is ranked higher than
87% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. GILD: 50.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
GILD' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 41.7 Max: 162.8
Current: 50.2
0
162.8
3-Year EBITDA Growth Rate 70.30
GILD's 3-Year EBITDA Growth Rate is ranked higher than
91% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. GILD: 70.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
GILD' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -29.8  Med: 38.05 Max: 116.7
Current: 70.3
-29.8
116.7
3-Year EPS without NRI Growth Rate 76.40
GILD's 3-Year EPS without NRI Growth Rate is ranked higher than
94% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: -1.40 vs. GILD: 76.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
GILD' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -19.7  Med: 30.35 Max: 143.5
Current: 76.4
-19.7
143.5
GuruFocus has detected 3 Warning Signs with Gilead Sciences Inc GILD.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» GILD's 30-Y Financials

Financials (Next Earnings Date: 2018-02-07)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2016

GILD Guru Trades in Q4 2016

Tom Gayner 14,000 sh (New)
Paul Tudor Jones 11,401 sh (+307.18%)
Jim Simons 5,274,948 sh (+170.92%)
Jerome Dodson 490,000 sh (+40.00%)
Jeff Auxier 5,477 sh (+14.53%)
Murray Stahl 13,000 sh (+12.55%)
Joel Greenblatt 1,025,203 sh (+11.01%)
Lee Ainslie 8,520 sh (+8.12%)
John Rogers 1,584,199 sh (+3.37%)
Ken Fisher 455,496 sh (+2.47%)
Mario Gabelli 12,414 sh (unchged)
Ronald Muhlenkamp 14,800 sh (unchged)
Julian Robertson 38,511 sh (unchged)
T Rowe Price Equity Income Fund 1,425,000 sh (unchged)
First Eagle Investment 300 sh (unchged)
First Eagle Investment 49,700 sh (unchged)
David Carlson 730,000 sh (unchged)
Steven Cohen Sold Out
John Burbank Sold Out
Ronald Muhlenkamp 212,995 sh (-0.70%)
David Dreman 20,724 sh (-5.18%)
John Buckingham 59,446 sh (-5.63%)
Dodge & Cox 3,250 sh (-13.33%)
Zeke Ashton 21,000 sh (-16.00%)
Pioneer Investments 2,722,308 sh (-17.35%)
Jeremy Grantham 874,684 sh (-24.97%)
NWQ Managers 61,056 sh (-25.45%)
Ray Dalio 80,272 sh (-74.54%)
Eaton Vance Worldwide Health Sciences Fund 550,067 sh (-13.41%)
» More
Q1 2017

GILD Guru Trades in Q1 2017

Charles Brandes 108,756 sh (New)
John Hussman 50,000 sh (New)
Steven Cohen 566,100 sh (New)
Tom Gayner 27,000 sh (+92.86%)
Paul Tudor Jones 20,709 sh (+81.64%)
T Rowe Price Equity Income Fund 2,560,000 sh (+79.65%)
Jim Simons 7,707,248 sh (+46.11%)
Jerome Dodson 601,000 sh (+22.65%)
Jeff Auxier 6,677 sh (+21.91%)
First Eagle Investment 59,700 sh (+20.12%)
Joel Greenblatt 1,212,036 sh (+18.22%)
John Rogers 1,800,201 sh (+13.63%)
Mario Gabelli 14,080 sh (+13.42%)
Lee Ainslie 9,460 sh (+11.03%)
John Buckingham 63,635 sh (+7.05%)
Ronald Muhlenkamp 225,725 sh (+5.98%)
Murray Stahl 13,600 sh (+4.62%)
Ronald Muhlenkamp 28,600 sh (unchged)
Julian Robertson 38,511 sh (unchged)
First Eagle Investment 300 sh (unchged)
Dodge & Cox 3,250 sh (unchged)
Steven Cohen 28,700 sh (unchged)
David Carlson 730,000 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 550,067 sh (unchged)
Zeke Ashton Sold Out
Ray Dalio Sold Out
Ken Fisher 451,634 sh (-0.85%)
David Dreman 20,174 sh (-2.65%)
NWQ Managers 52,811 sh (-13.50%)
Pioneer Investments 1,898,063 sh (-30.28%)
Jeremy Grantham 37,400 sh (-95.72%)
» More
Q2 2017

GILD Guru Trades in Q2 2017

Manning & Napier Advisors, Inc 214,432 sh (New)
Lee Ainslie 24,760 sh (+161.73%)
Steven Cohen 1,272,910 sh (+124.86%)
Pioneer Investments 3,493,148 sh (+84.04%)
Jim Simons 10,407,848 sh (+35.04%)
T Rowe Price Equity Income Fund 3,270,900 sh (+27.77%)
Tom Gayner 33,000 sh (+22.22%)
John Rogers 2,090,813 sh (+16.14%)
Jerome Dodson 646,000 sh (+7.49%)
John Buckingham 67,601 sh (+6.23%)
Ken Fisher 460,155 sh (+1.89%)
Charles Brandes 110,720 sh (+1.81%)
Jeff Auxier 6,773 sh (+1.44%)
Mario Gabelli 14,080 sh (unchged)
First Eagle Investment 59,700 sh (unchged)
First Eagle Investment 300 sh (unchged)
Ronald Muhlenkamp 25,600 sh (unchged)
Dodge & Cox 3,250 sh (unchged)
Julian Robertson 38,511 sh (unchged)
Steven Cohen 28,700 sh (unchged)
Steven Cohen 500,000 sh (unchged)
Paul Tudor Jones Sold Out
Ronald Muhlenkamp 225,685 sh (-0.02%)
David Carlson 700,000 sh (-4.11%)
NWQ Managers 45,800 sh (-13.28%)
Joel Greenblatt 963,721 sh (-20.49%)
Murray Stahl 9,400 sh (-30.88%)
David Dreman 12,145 sh (-39.80%)
John Hussman 25,000 sh (-50.00%)
Jeremy Grantham 6,800 sh (-81.82%)
Eaton Vance Worldwide Health Sciences Fund 464,801 sh (-15.50%)
» More
Q3 2017

GILD Guru Trades in Q3 2017

Richard Pzena 2,869 sh (New)
Dodge & Cox 9,909,731 sh (+304814.80%)
NWQ Managers 459,307 sh (+902.85%)
Pioneer Investments 5,906,557 sh (+69.09%)
Jeff Auxier 8,130 sh (+20.04%)
John Rogers 2,169,437 sh (+3.76%)
Ken Fisher 469,400 sh (+2.01%)
John Buckingham 68,747 sh (+1.70%)
Jerome Dodson 646,000 sh (unchged)
Tom Gayner 33,000 sh (unchged)
First Eagle Investment 59,700 sh (unchged)
First Eagle Investment 300 sh (unchged)
Ronald Muhlenkamp 25,600 sh (unchged)
Julian Robertson 38,511 sh (unchged)
Murray Stahl 9,400 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 464,801 sh (unchged)
John Hussman Sold Out
Lee Ainslie Sold Out
Jeremy Grantham Sold Out
Steven Cohen Sold Out
Ronald Muhlenkamp 224,147 sh (-0.68%)
Jim Simons 10,230,899 sh (-1.70%)
Mario Gabelli 13,580 sh (-3.55%)
T Rowe Price Equity Income Fund 3,070,000 sh (-6.14%)
David Dreman 10,932 sh (-9.99%)
Manning & Napier Advisors, Inc 189,381 sh (-11.68%)
Joel Greenblatt 696,622 sh (-27.72%)
Charles Brandes 70,262 sh (-36.54%)
David Carlson 370,000 sh (-47.14%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:GILD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Dodge & Cox 2017-09-30 Add 304814.80%0.65%$69.25 - $85.47 $ 72.82-5%9,909,731
T Rowe Price Equity Income Fund 2017-09-30 Reduce -6.14%0.07%$69.25 - $85.47 $ 72.82-5%3,070,000
John Rogers 2017-09-30 Add 3.76%0.07%$69.25 - $85.47 $ 72.82-5%2,169,437
Joel Greenblatt 2017-09-30 Reduce -27.72%0.27%$69.25 - $85.47 $ 72.82-5%696,622
Ken Fisher 2017-09-30 Add 2.01%$69.25 - $85.47 $ 72.82-5%469,400
NWQ Managers 2017-09-30 Add 902.85%0.49%$69.25 - $85.47 $ 72.82-5%459,307
Ronald Muhlenkamp 2017-09-30 Reduce -0.68%0.03%$69.25 - $85.47 $ 72.82-5%224,147
Charles Brandes 2017-09-30 Reduce -36.54%0.04%$69.25 - $85.47 $ 72.82-5%70,262
Mario Gabelli 2017-09-30 Reduce -3.55%$69.25 - $85.47 $ 72.82-5%13,580
David Dreman 2017-09-30 Reduce -9.99%0.05%$69.25 - $85.47 $ 72.82-5%10,932
Richard Pzena 2017-09-30 New Buy$69.25 - $85.47 $ 72.82-5%2,869
T Rowe Price Equity Income Fund 2017-06-30 Add 27.77%0.23%$64.12 - $71.92 $ 72.8210%3,270,900
John Rogers 2017-06-30 Add 16.14%0.24%$64.12 - $71.92 $ 72.8210%2,090,813
Joel Greenblatt 2017-06-30 Reduce -20.49%0.22%$64.12 - $71.92 $ 72.8210%963,721
Ken Fisher 2017-06-30 Add 1.89%$64.12 - $71.92 $ 72.8210%460,155
Ronald Muhlenkamp 2017-06-30 Reduce -0.02%$64.12 - $71.92 $ 72.8210%225,685
Charles Brandes 2017-06-30 Add 1.81%$64.12 - $71.92 $ 72.8210%110,720
NWQ Managers 2017-06-30 Reduce -13.28%0.01%$64.12 - $71.92 $ 72.8210%45,800
Tom Gayner 2017-06-30 Add 22.22%0.01%$64.12 - $71.92 $ 72.8210%33,000
David Dreman 2017-06-30 Reduce -39.80%0.31%$64.12 - $71.92 $ 72.8210%12,145
T Rowe Price Equity Income Fund 2017-03-31 Add 79.65%0.35%$65.59 - $76.38 $ 72.824%2,560,000
John Rogers 2017-03-31 Add 13.63%0.17%$65.59 - $76.38 $ 72.824%1,800,201
Joel Greenblatt 2017-03-31 Add 18.22%0.16%$65.59 - $76.38 $ 72.824%1,212,036
Ken Fisher 2017-03-31 Reduce -0.85%$65.59 - $76.38 $ 72.824%451,634
Ronald Muhlenkamp 2017-03-31 Add 5.98%0.27%$65.59 - $76.38 $ 72.824%225,725
Charles Brandes 2017-03-31 New Buy0.11%$65.59 - $76.38 $ 72.824%108,756
First Eagle Investment 2017-03-31 Add 20.12%$65.59 - $76.38 $ 72.824%59,700
NWQ Managers 2017-03-31 Reduce -13.50%0.01%$65.59 - $76.38 $ 72.824%52,811
Tom Gayner 2017-03-31 Add 92.86%0.02%$65.59 - $76.38 $ 72.824%27,000
David Dreman 2017-03-31 Reduce -2.65%0.02%$65.59 - $76.38 $ 72.824%20,174
Mario Gabelli 2017-03-31 Add 13.42%$65.59 - $76.38 $ 72.824%14,080
John Rogers 2016-12-31 Add 3.37%0.04%$71.61 - $78.47 $ 72.82-2%1,584,199
Joel Greenblatt 2016-12-31 Add 11.01%0.09%$71.61 - $78.47 $ 72.82-2%1,025,203
Ken Fisher 2016-12-31 Add 2.47%$71.61 - $78.47 $ 72.82-2%455,496
Ronald Muhlenkamp 2016-12-31 Reduce -0.70%0.04%$71.61 - $78.47 $ 72.82-2%212,995
NWQ Managers 2016-12-31 Reduce -25.45%0.02%$71.61 - $78.47 $ 72.82-2%61,056
David Dreman 2016-12-31 Reduce -5.18%0.05%$71.61 - $78.47 $ 72.82-2%20,724
Tom Gayner 2016-12-31 New Buy0.02%$71.61 - $78.47 $ 72.82-2%14,000
Dodge & Cox 2016-12-31 Reduce -13.33%$71.61 - $78.47 $ 72.82-2%3,250
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:NAS:CELG, NAS:AMGN, OCSE:NOVO B, NAS:BIIB, ASX:CSL, NAS:REGN, LSE:SHP, NAS:VRTX, XSWX:ATLN, NAS:ALXN, NAS:INCY, XKRX:207940, XKRX:068270, XMCE:GRF.P, OCSE:NZYM B, SZSE:002252, NAS:BMRN, XBRU:UCB, OCSE:GEN, NAS:ALNY » details
Traded in other countries:GILD.Austria, GILD34.Brazil, GILD.Chile, GIS.Germany, GILD.Italy, GILD.Mexico, GILD.Switzerland,
Headquarter Location:USA
Gilead Sciences Inc is a biopharmaceutical company that discovers, develops and commercializes new medicines in areas of unmet medical need. Its products target a number of areas, such as HIV, liver diseases, cardiovascular and other diseases.

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite acquisition boosted Gilead's exposure to cell therapy in oncology.

Guru Investment Theses on Gilead Sciences Inc

Jerome Dodson Comments on Gilead Sciences - Oct 25, 2017

Our best performer was Gilead Sciences (NASDAQ:GILD), the biotechnology firm that makes therapies for HIV and hepatitis C. Its stock jumped 14.5% from $70.78 to $81.02, contributing 70 basis points to the Fund’s return. In August, the company acquired Kite Pharma for $12 billion. Kite Pharma is a leader in cellular therapy, a game-changing new cancer treatment that harnesses the body’s own immune system to fight cancer. The acquisition establishes Gilead as a leader in a fast-growing field with huge opportunities.



From Jerome Dodson (Trades, Portfolio)'s Parnassus Fund third quarter 2017 commentary.

Check out Jerome Dodson latest stock trades

Jerome Dodson Comments on Gilead - Jan 25, 2017

Our other laggard was Gilead (NASDAQ:GILD), a biotechnology firm that makes therapies for HIV and Hepatitis C. Gilead sliced 98 basis points off the Fund’s return, as its stock declined 29.2%, from $101.19 to $71.61. The stock dropped due to weakness in the Hepatitis C business, as pricing came under pressure due to increased competition, and the patient population fell because Gilead’s drugs cure patients of this damaging disease. The stock is on the bargain table, and the company has a strong balance sheet and a proven track record of innovation, so we increased our position throughout the year.



From the Parnassus Fund fourth quarter 2016 commentary.



Check out Jerome Dodson latest stock trades

Jerome Dodson Comments on Gilead - Jul 26, 2016

Gilead (NASDAQ:GILD), a biotechnology firm that makes therapies for HIV and hepatitis C, sliced 21 basis points off the Fund’s return, as its stock declined 9.2% from $91.86 to $83.42. The company’s underperformance was driven by weakness in its hepatitis C business, as pricing came under pressure due to increased competition. Given Gilead’s proven track record of innovation and its strong balance sheet, we believe the company has many opportunities, not only to maintain leadership in HIV and hepatitis C, but also to expand its portfolio into new therapeutic areas.


From Jerome Dodson (Trades, Portfolio)'s Parnassus Fund second quarter 2016 commentary.

Check out Jerome Dodson latest stock trades

John Rogers Comments on Gilead Sciences Inc. - Dec 02, 2015

Biotechnology leader Gilead Sciences, Inc. (NASDAQ:GILD) dropped -15.90% on recent concerns over drug pricing. Gilead actually reported quarterly earnings that were better than expected. We continue to hold the shares, based on our belief that the market is overly focused on pricing and underestimating future sales that we think are likely to grow.





From John Rogers (Trades, Portfolio) 3rd quarter commentary on the Ariel Global Fund.

Check out John Rogers latest stock trades

Top Ranked Articles about Gilead Sciences Inc

Jerome Dodson Comments on Gilead Sciences Guru stock highlight
Our best performer was Gilead Sciences (NASDAQ:GILD), the biotechnology firm that makes therapies for HIV and hepatitis C. Its stock jumped 14.5% from $70.78 to $81.02, contributing 70 basis points to the Fund’s return. In August, the company acquired Kite Pharma for $12 billion. Kite Pharma is a leader in cellular therapy, a game-changing new cancer treatment that harnesses the body’s own immune system to fight cancer. The acquisition establishes Gilead as a leader in a fast-growing field with huge opportunities.

Read more...
Detailed Research: Economic Perspectives on DexCom, Pier 1 Imports, Gilead Sciences, Fitbit, Cloudera, and GoPro – What Drives Growth in Today's Competitive Landscape
Let’s Talk About CAR-T A quick overview of treatment and the major players in bringing promising cancer-fighting technologies to market
For those interested in staying up to date with the latest developments in biotechnology it is impossible to overlook the developments of chimeric antigen receptor therapy (CAR-T) and the potential it holds for treating cancer. The most pivotal moment came on Aug. 30 when Novartis (NVS) announced approval for Kymriah™ (tisagenlecleucel) for treating children and young adults with B-cell acute lymphoblastic leukemia (ALL) that is refractory or has relapsed at least twice. Read more...
Is Muhlenkamp on a Roll Again? After a decade of dismal returns, the guru's performance has been strong over the past year
Novartis and the Future of Gene Therapy The company recently became the first to market a gene therapy for cancer
Gene therapy is now, finally, a new weapon in our arsenal against cancer partly thanks to, of all things, the HIV virus. The world’s first chimeric antigen receptor T-cell (CAR-T) treatment was approved by the Food and Drug Administration at the end of last month, a treatment developed by one Dr. Carl June at University of Pennsylvania in partnership with Novatris AG (NYSE:NVS). Read more...
Stock Score Reports for Chesapeake Energy, Ford, General Electric, Gilead Sciences and Snap Inc.
SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Kite Pharma, Inc. - KITE
UQM Technologies, Kite Pharma Jump on Monday Kite, Gilead gain on acquisition news
The U.S. stock market opened mixed with investors looking to the impact of Hurricane Harvey. Read more...
Pioneer Investments Buys Citigroup, Berkshire, Gilead The guru's largest 2nd-quarter investments
Pioneer Investments (TradesPortfolio) operates in wide areas of investment vehicles – mutual funds, single manager hedge funds, funds of hedge funds, structured products, segregated and managed accounts, institutional funds. During the second quarter the firm bought shares in the following stocks: Read more...
9 Stocks Tom Gayner Keeps Buying The guru bought these stocks in the last 2 quarters
Markel's Tom Gayner (Trades, Portfolio) bought the following stocks in both the first and second quarters of 2017:  Read more...

Ratios

vs
industry
vs
history
PE Ratio 8.26
GILD's PE Ratio is ranked higher than
90% of the 247 Companies
in the Global Biotechnology industry.

( Industry Median: 29.02 vs. GILD: 8.26 )
Ranked among companies with meaningful PE Ratio only.
GILD' s PE Ratio Range Over the Past 10 Years
Min: 6.67  Med: 14.72 Max: 45.49
Current: 8.26
6.67
45.49
Forward PE Ratio 10.63
GILD's Forward PE Ratio is ranked higher than
85% of the 68 Companies
in the Global Biotechnology industry.

( Industry Median: 24.21 vs. GILD: 10.63 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 8.26
GILD's PE Ratio without NRI is ranked higher than
91% of the 245 Companies
in the Global Biotechnology industry.

( Industry Median: 29.70 vs. GILD: 8.26 )
Ranked among companies with meaningful PE Ratio without NRI only.
GILD' s PE Ratio without NRI Range Over the Past 10 Years
Min: 6.67  Med: 14.66 Max: 45.49
Current: 8.26
6.67
45.49
Price-to-Owner-Earnings 8.59
GILD's Price-to-Owner-Earnings is ranked higher than
88% of the 145 Companies
in the Global Biotechnology industry.

( Industry Median: 38.46 vs. GILD: 8.59 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
GILD' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 5.62  Med: 13.45 Max: 54.5
Current: 8.59
5.62
54.5
PB Ratio 3.82
GILD's PB Ratio is ranked lower than
55% of the 923 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. GILD: 3.82 )
Ranked among companies with meaningful PB Ratio only.
GILD' s PB Ratio Range Over the Past 10 Years
Min: 3.69  Med: 7.78 Max: 18.71
Current: 3.82
3.69
18.71
PS Ratio 3.48
GILD's PS Ratio is ranked higher than
76% of the 706 Companies
in the Global Biotechnology industry.

( Industry Median: 11.76 vs. GILD: 3.48 )
Ranked among companies with meaningful PS Ratio only.
GILD' s PS Ratio Range Over the Past 10 Years
Min: 2.95  Med: 6.2 Max: 12.5
Current: 3.48
2.95
12.5
Price-to-Free-Cash-Flow 8.14
GILD's Price-to-Free-Cash-Flow is ranked higher than
89% of the 140 Companies
in the Global Biotechnology industry.

( Industry Median: 36.07 vs. GILD: 8.14 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
GILD' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 5.66  Med: 14.33 Max: 48.02
Current: 8.14
5.66
48.02
Price-to-Operating-Cash-Flow 7.79
GILD's Price-to-Operating-Cash-Flow is ranked higher than
91% of the 188 Companies
in the Global Biotechnology industry.

( Industry Median: 25.45 vs. GILD: 7.79 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
GILD' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.41  Med: 13.7 Max: 45.09
Current: 7.79
5.41
45.09
EV-to-EBIT 5.87
GILD's EV-to-EBIT is ranked higher than
85% of the 253 Companies
in the Global Biotechnology industry.

( Industry Median: 23.72 vs. GILD: 5.87 )
Ranked among companies with meaningful EV-to-EBIT only.
GILD' s EV-to-EBIT Range Over the Past 10 Years
Min: -154.2  Med: 10.7 Max: 209.2
Current: 5.87
-154.2
209.2
EV-to-EBITDA 5.48
GILD's EV-to-EBITDA is ranked higher than
83% of the 280 Companies
in the Global Biotechnology industry.

( Industry Median: 19.29 vs. GILD: 5.48 )
Ranked among companies with meaningful EV-to-EBITDA only.
GILD' s EV-to-EBITDA Range Over the Past 10 Years
Min: -189.9  Med: 10.1 Max: 168
Current: 5.48
-189.9
168
EV-to-Revenue 3.49
GILD's EV-to-Revenue is ranked higher than
78% of the 752 Companies
in the Global Biotechnology industry.

( Industry Median: 12.83 vs. GILD: 3.49 )
Ranked among companies with meaningful EV-to-Revenue only.
GILD' s EV-to-Revenue Range Over the Past 10 Years
Min: 3.1  Med: 6.4 Max: 13.1
Current: 3.49
3.1
13.1
PEG Ratio 0.15
GILD's PEG Ratio is ranked higher than
97% of the 101 Companies
in the Global Biotechnology industry.

( Industry Median: 2.09 vs. GILD: 0.15 )
Ranked among companies with meaningful PEG Ratio only.
GILD' s PEG Ratio Range Over the Past 10 Years
Min: 0.11  Med: 0.39 Max: 3.81
Current: 0.15
0.11
3.81
Shiller PE Ratio 15.32
GILD's Shiller PE Ratio is ranked higher than
89% of the 70 Companies
in the Global Biotechnology industry.

( Industry Median: 41.36 vs. GILD: 15.32 )
Ranked among companies with meaningful Shiller PE Ratio only.
GILD' s Shiller PE Ratio Range Over the Past 10 Years
Min: 14.15  Med: 49.4 Max: 2078
Current: 15.32
14.15
2078
Current Ratio 3.68
GILD's Current Ratio is ranked lower than
57% of the 1008 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. GILD: 3.68 )
Ranked among companies with meaningful Current Ratio only.
GILD' s Current Ratio Range Over the Past 10 Years
Min: 1.09  Med: 6.95 Max: 57.67
Current: 3.68
1.09
57.67
Quick Ratio 3.56
GILD's Quick Ratio is ranked lower than
56% of the 1007 Companies
in the Global Biotechnology industry.

( Industry Median: 3.83 vs. GILD: 3.56 )
Ranked among companies with meaningful Quick Ratio only.
GILD' s Quick Ratio Range Over the Past 10 Years
Min: 0.83  Med: 6.47 Max: 57.67
Current: 3.56
0.83
57.67
Days Inventory 130.89
GILD's Days Inventory is ranked lower than
52% of the 473 Companies
in the Global Biotechnology industry.

( Industry Median: 134.39 vs. GILD: 130.89 )
Ranked among companies with meaningful Days Inventory only.
GILD' s Days Inventory Range Over the Past 10 Years
Min: 130.89  Med: 221.48 Max: 276.35
Current: 130.89
130.89
276.35
Days Sales Outstanding 54.75
GILD's Days Sales Outstanding is ranked higher than
58% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: 67.34 vs. GILD: 54.75 )
Ranked among companies with meaningful Days Sales Outstanding only.
GILD' s Days Sales Outstanding Range Over the Past 10 Years
Min: 54.22  Med: 69.31 Max: 84.93
Current: 54.75
54.22
84.93
Days Payable 60.63
GILD's Days Payable is ranked higher than
59% of the 434 Companies
in the Global Biotechnology industry.

( Industry Median: 57.10 vs. GILD: 60.63 )
Ranked among companies with meaningful Days Payable only.
GILD' s Days Payable Range Over the Past 10 Years
Min: 60.63  Med: 158.55 Max: 207.21
Current: 60.63
60.63
207.21

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 2.80
GILD's Dividend Yield % is ranked higher than
88% of the 240 Companies
in the Global Biotechnology industry.

( Industry Median: 1.24 vs. GILD: 2.80 )
Ranked among companies with meaningful Dividend Yield % only.
GILD' s Dividend Yield % Range Over the Past 10 Years
Min: 0.36  Med: 2.21 Max: 3.09
Current: 2.8
0.36
3.09
Dividend Payout Ratio 0.23
GILD's Dividend Payout Ratio is ranked higher than
82% of the 133 Companies
in the Global Biotechnology industry.

( Industry Median: 0.39 vs. GILD: 0.23 )
Ranked among companies with meaningful Dividend Payout Ratio only.
GILD' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.11  Med: 0.15 Max: 0.23
Current: 0.23
0.11
0.23
Forward Dividend Yield % 2.87
GILD's Forward Dividend Yield % is ranked higher than
87% of the 224 Companies
in the Global Biotechnology industry.

( Industry Median: 1.25 vs. GILD: 2.87 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 2.80
GILD's 5-Year Yield-on-Cost % is ranked higher than
71% of the 305 Companies
in the Global Biotechnology industry.

( Industry Median: 1.61 vs. GILD: 2.80 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
GILD' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.36  Med: 2.21 Max: 3.09
Current: 2.8
0.36
3.09
3-Year Average Share Buyback Ratio 5.10
GILD's 3-Year Average Share Buyback Ratio is ranked higher than
99% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. GILD: 5.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
GILD' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -25.6  Med: -3.9 Max: 6.1
Current: 5.1
-25.6
6.1

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 6.21
GILD's Price-to-Tangible-Book is ranked lower than
67% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 5.09 vs. GILD: 6.21 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
GILD' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.51  Med: 8.49 Max: 214.73
Current: 6.21
1.51
214.73
Price-to-Intrinsic-Value-Projected-FCF 0.54
GILD's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
95% of the 171 Companies
in the Global Biotechnology industry.

( Industry Median: 3.43 vs. GILD: 0.54 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
GILD' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.54  Med: 1.95 Max: 20.83
Current: 0.54
0.54
20.83
Price-to-Median-PS-Value 0.56
GILD's Price-to-Median-PS-Value is ranked higher than
75% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. GILD: 0.56 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
GILD' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.5  Med: 1.9 Max: 45
Current: 0.56
0.5
45
Price-to-Peter-Lynch-Fair-Value 0.33
GILD's Price-to-Peter-Lynch-Fair-Value is ranked higher than
98% of the 65 Companies
in the Global Biotechnology industry.

( Industry Median: 1.79 vs. GILD: 0.33 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
GILD' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.29  Med: 0.87 Max: 9.13
Current: 0.33
0.29
9.13
Price-to-Graham-Number 1.51
GILD's Price-to-Graham-Number is ranked higher than
72% of the 185 Companies
in the Global Biotechnology industry.

( Industry Median: 2.69 vs. GILD: 1.51 )
Ranked among companies with meaningful Price-to-Graham-Number only.
GILD' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.51  Med: 3.4 Max: 15.78
Current: 1.51
1.51
15.78
Earnings Yield (Greenblatt) % 17.01
GILD's Earnings Yield (Greenblatt) % is ranked higher than
96% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -7.65 vs. GILD: 17.01 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
GILD' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -2.1  Med: 7.9 Max: 18.8
Current: 17.01
-2.1
18.8
Forward Rate of Return (Yacktman) % 64.46
GILD's Forward Rate of Return (Yacktman) % is ranked higher than
98% of the 132 Companies
in the Global Biotechnology industry.

( Industry Median: 13.13 vs. GILD: 64.46 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
GILD' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 1.4  Med: 10.9 Max: 71
Current: 64.46
1.4
71

More Statistics

Revenue (TTM) (Mil) $27,478.00
EPS (TTM) $ 8.79
Beta0.84
Short Percentage of Float1.51%
52-Week Range $63.76 - 86.27
Shares Outstanding (Mil)1,306.27

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 25,857 22,107 21,326 22,546
EPS ($) 8.71 6.88 6.64 7.25
EPS without NRI ($) 8.71 6.88 6.64 7.25
EPS Growth Rate
(Future 3Y To 5Y Estimate)
6.98%
Dividends per Share ($) 1.30 1.37 1.88

Piotroski F-Score Details

Piotroski F-Score: 66
Positive ROAY
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyY
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}